Online citations, reference lists, and bibliographies.
← Back to Search

Dynamic Contrast-enhanced CT For The Assessment Of Tumour Response In Malignant Pleural Mesothelioma: A Pilot Study

E. Gudmundsson, Z. Labby, C. Straus, W. Sensakovic, Feng Li, B. Rose, A. Cunliffe, H. Kindler, S. Armato
Published 2018 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
ObjectivesThe aim of this pilot study was to investigate the utility of haemodynamic parameters derived from dynamic contrast-enhanced computed tomography (DCE-CT) scans in the assessment of tumour response to treatment in malignant pleural mesothelioma (MPM) patients.MethodsThe patient cohort included nine patients undergoing chemotherapy and five patients on observation. Each patient underwent two DCE-CT scans separated by approximately 2 months. The DCE-CT parameters of tissue blood flow (BF) and tissue blood volume (BV) were obtained within the dynamically imaged tumour. Mean relative changes in tumour DCE-CT parameters between scans were compared between the on-treatment and on-observation cohorts. DCE-CT parameter changes were correlated with relative change in tumour bulk evaluated according to the modified RECIST protocol.ResultsDiffering trends in relative change in BF and BV between scans were found between the two patient groups (p = 0.19 and p = 0.06 for BF and BV, respectively). No significant rank correlations were found when comparing relative changes in DCE-CT parameters with relative change in tumour bulk.ConclusionsDiffering trends in the relative change of BF and BV between patients on treatment and on observation indicate the potential of DCE-CT for the assessment of pharmacodynamic endpoints with respect to treatment in MPM. A future study with a larger patient cohort and unified treatment regimens should be undertaken to confirm the results of this pilot study.Key Points• CT-derived haemodynamic parameters show differing trends between malignant pleural mesothelioma patients on treatment and patients off treatment• Changes in haemodynamic parameters do not correlate with changes in tumour bulk as measured according to the modified RECIST protocol• Differing trends across the two patient groups indicate the potential sensitivity of DCE-CT to assess pharmacodynamic endpoints in the treatment of MPM
This paper references
10.1016/j.ctrv.2014.10.007
Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies.
J. Remon (2015)
10.1148/RADIOLOGY.137.3.7003648
Cerebral blood flow determination by rapid-sequence computed tomography: theoretical analysis.
L. Axel (1980)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural
BNJ Vogelzang (2008)
10.1007/BF02967383
New guidelines to evaluate the response to treatment in solid tumors
P. Therasse (2000)
10.1016/J.LUNGCAN.2005.12.013
Modeling of mesothelioma growth demonstrates weaknesses of current response criteria.
G. Oxnard (2006)
10.1158/1078-0432.CCR-09-1624
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
J. Wolchok (2009)
10.1097/00004424-199311001-00023
Contrast Bolus Dynamic Computed Tomography for the Measurement of Solid Organ Perfusion
M. Blomley (1993)
10.1148/rg.346130089
Multimodality imaging for characterization, classification, and staging of malignant pleural mesothelioma.
Larry T Nickell (2014)
10.2214/AJR.09.3462
Estimating effective dose for CT using dose-length product compared with using organ doses: consequences of adopting International Commission on Radiological Protection publication 103 or dual-energy scanning.
J. Christner (2010)
10.1016/j.critrevonc.2010.04.004
Malignant pleural mesothelioma: the standard of care and challenges for future management.
J. Van Meerbeeck (2011)
2004)Modified RECISTcriteria for assessment of response in malignant pleural mesothelioma
ByrneMJ (2004)
Modified RECISTcriteria for assessment of response in malignant pleural mesothelioma
AK Nowak (2004)
10.1200/JCO.2011.41.5869
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
H. Kindler (2012)
10.1080/01621459.1972.10481279
Constructing Confidence Sets Using Rank Statistics
D. Bauer (1972)
10.1016/j.neuroimage.2010.09.025
A reproducible evaluation of ANTs similarity metric performance in brain image registration
B. Avants (2011)
10.1016/S0140-6736(15)01238-6
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
G. Zalcman (2016)
10.1093/ANNONC/MDH059
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
10.1183/09031936.00146110
Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma?
T. Frauenfelder (2011)
10.1093/annonc/mds535
Disease volumes as a marker for patient response in malignant pleural mesothelioma.
Z. Labby (2013)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1148/radiol.2483071964
Converting dose-length product to effective dose at CT.
W. Huda (2008)
10.1097/JTO.0000000000000376
Dynamic Volume Perfusion Computed Tomography Parameters versus RECIST for the Prediction of Outcome in Lung Cancer Patients Treated with Conventional Chemotherapy
S. Sudarski (2015)
10.1007/s00330-006-0425-9
The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients
M. Meijerink (2006)
10.1093/annonc/mdp466
Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib.
R. Thiam (2010)
10.1259/BJR/13564625
Perfusion CT: a worthwhile enhancement?
K. Miles (2003)
10.1097/RCT.0b013e318245c23c
Computed Tomographic Perfusion Imaging for the Therapeutic Response of Chemoembolization for Hepatocellular Carcinoma
L. Yang (2012)
10.1214/AOMS/1177704172
Estimates of Location Based on Rank Tests
J. L. Hodges (1963)
10.1148/RADIOLOGY.209.1.9769817
Perfusion CT of the brain: diagnostic approach for early detection of ischemic stroke.
M. Koenig (1998)
The Bonferonni and Šidák Corrections for Multiple Comparisons
H. Abdi (2006)
10.1097/JTO.0b013e3181dd0ef1
Assessment of Therapy Responses and Prediction of Survival in Malignant Pleural Mesothelioma Through Computer-Aided Volumetric Measurement on Computed Tomography Scans
F. Liu (2010)
10.1016/j.ejrad.2015.03.022
Perfusion CT imaging of treatment response in oncology.
D. Prezzi (2015)
10.2214/AJR.11.7483
Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST.
M. Nishino (2012)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar